STAT3 and neoplasm: An inhibitor of STAT3, WP1066, has been recently shown to have anti-tumor activity in histone H3 G34R-mutant HGG, a subtype of HGG most commonly occurring in teenage and young adult patients (107), and is currently being evaluated in clinical trials (NCT01904123 and NCT04334863).